Item 2.02 Results of Operations and Financial Condition
As discussed below, in connection with participation in the 39th Annual J.P.
Morgan Healthcare Conference, Aprea Therapeutics, Inc. (the "Company") updated
its corporate presentation to include disclosure that the Company had $89.0
million of cash and cash equivalents (unaudited) as of December 31, 2020.
Because the Company's consolidated financial statements for the year ended
December 31, 2020 have not yet been finalized or audited, the preliminary
statement of the Company's cash and cash equivalents as of December 31, 2020 in
this Item 2.02 is subject to change, and the Company's actual cash and cash
equivalents as of December 31, 2020 may differ materially from this preliminary
estimate. Accordingly, you should not place undue reliance on this preliminary
estimate.
Item 7.01 Regulation FD Disclosure
Beginning on January 12, 2021, the Company will participate in the 39th Annual
J.P. Morgan Healthcare Conference. The Company has updated its corporate
presentation that it intends to use in connection with its presentation on
Tuesday January 12, 2020 at 2:50 p.m. Eastern Time in meetings with investors.
The updates primarily include updates on the Company's ongoing and planned
clinical trials and disclosure regarding the Company's cash and cash equivalents
as of December 31, 2020.
A copy of the Company's corporate presentation is attached hereto as Exhibit
99.1 and is hereby incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Aprea Therapeutics, Inc. Presentation
© Edgar Online, source Glimpses